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KAJIAN RAWAK, DUBEL-BUTA DAN TERKAWALKAN PLASEBO KE 
ATAS KEBERKESANAN BIFIDOBACTERIUM LONGUM BB536 DALAM 
MENGURANGKAN GEJALA PENYAKIT PERNAFASAN DAN 
GASTROUSUS DALAM KALANGAN KANAK-KANAK 
 
 
ABSTRAK 
Probiotik telah digunakan secara meluas dan mungkin berkesan dalam 
meringankan gejala dan mengurangkan kejadian penyakit pernafasan dan gastrousus, 
tetapi keberkesanannya masih kontroversi disebabkan kebergantungan kepada strain 
dan perumah. Kanak-kanak yang menghadiri pusat jagaan harian adalah berisiko 1.5-
3.0 kali lebih tinggi dijangkiti penyakit pernafasan dan gastrousus dibandingkan 
mereka yang tidak menghadiri pusat jagaan harian. Kajian percubaan rawak, dubel-
buta dan terkawalkan plasebo yang telah dilakukan bagi tempoh 10 bulan ini bertujuan 
untuk mengkaji kesan pengambilan Bifidobacterium longum BB536 dalam mencegah 
kejadian cirit-birit akut dan / atau penyakit yang berkaitan dengan sistem pernafasan 
dalam kalangan kanak-kanak muda di Malaysia. Seramai 520 kanak-kanak muda yang 
sihat berumur dari 2 hingga 6 tahun telah direkrut dan diagihkan secara rawak kepada 
dua kumpulan untuk menerima sama ada serbuk BB536 dalam dos tetap sebanyak 
5x109 CFU/hari atau serbuk plasebo, selama lima hari seminggu bagi tempoh 10 bulan. 
Serbuk BB536 dan plasebo tersebut yang diimport daripada Morinaga Milk Industry 
Co. Ltd, Japan, telah dihasilkan oleh loji perkilangan yang telah mendapat pensijilan 
sistem analisis hazard dan titik kawalan kritikal (HACCP). Serbuk BB536 
mengandungi probiotik Bifidobacterium longum BB536 dan dekstrin sebagai 
penghantar manakala plasebo mengandungi 100% dekstrin. Soal selidik dasar 
(Soalselidik Maklumat Asas dan Gayahidup) diagihkan dan dikumpulkan sebelum 
xv 
 
intervensi manakala soal selidik bulanan (Soalselidik Kesihatan Bulanan) diagihkan 
dan dikumpulkan setiap bulan. Sampel najis telah dikutip pada bulan ke-0, 5 dan 10 
kajian untuk analisis profil mikrobiota usus dan kepekatan immunoglobulin A (IgA) 
fekal. Keputusan menunjukkan tiada perbezaan yang signifikan dalam insiden dan 
gejala cirit-birit antara kumpulan BB536 dan kumpulan plasebo. Perbandingan gejala 
jangkitan pernafasan menunjukkan pengurangan yang signifikan (P<0.05) dalam 
gejala sakit tekak (P = 0.018), tetapi tiada pengurangan signifikan untuk demam (P = 
0.084), batuk (P = 0.087) dan hidung berair (P = 0.087) dalam kumpulan BB536 
berbanding dengan kumpulan plasebo pada tahap keyakinan 95%. Sampel najis 
dianalisis melalui amplikon penjujukan pemprosesan tinggi yang diperolehi dari 
rantau V3-V4 gen 16S rRNA. Perbandingan kelimpahan relatif bagi spesies 
menunjukkan peningkatan signifikan dalam kelimpahan genus Bacteroides dan 
Prevotella selepas pengambilan BB536, yang diandaikan bertanggungjawab dalam 
pengawalan tindak balas imun dalam paru-paru melalui penghasilan asid lemak 
berantai pendek. Analisis koordinat prinsipal menunjukkan corak pengelompokan 
mikrobiota usus yang signifikan di peringkat genus dalam kumpulan BB536 di mana 
mikrobiota berkelompok bersama-sama manakala kumpulan plasebo menunjukkan 
corak yang lebih tersebar, menunjukkan bahawa komposisi mikrobiota lebih serupa 
dalam kumpulan rawatan. Kepekatan immunoglobulin A dalam sampel najis tidak 
berbeza secara signifikan antara kumpulan plasebo dan kumpulan BB536. Kedua-dua 
kumpulan menunjukkan peningkatan dalam kepekatan IgA pada musim hujan apabila 
kecenderungan untuk jangkitan adalah lebih tinggi. Kesimpulannya, keputusan ini 
menunjukkan bahawa pengambilan BB536 boleh mengurangkan sakit tekak semasa 
jangkitan pernafasan, tetapi tiada kesan dalam mengubah komposisi mikrobiota usus 
dalam kalangan kanak-kanak di Malaysia.  
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A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY 
ON THE EFFICACY OF BIFIDOBACTERIUM LONGUM BB536 IN 
REDUCING SYMPTOMS OF RESPIRATORY AND GASTROINTESTINAL 
DISEASES AMONG YOUNG CHILDREN 
 
 
ABSTRACT 
 Probiotics have been extensively used and may be effective in alleviating 
symptoms and reducing the occurrences of gastrointestinal and respiratory diseases, 
but their efficacy remains controversial due to strain and host dependency. Children 
who are attending day care centres have 1.5 to 3.0 times higher risk of getting 
respiratory and gastrointestinal diseases than those who are not attending day care 
centres. This randomized, double-blind and placebo-controlled trial which was carried 
out for a period of 10 months was aimed to evaluate the effects of oral administration 
of Bifidobacterium longum BB536 in preventing acute diarrhea and/or respiratory-
related diseases among young children in Malaysia. A total of 520 healthy young 
children aged from 2 to 6 years were recruited and randomized into two groups to 
receive either BB536 powder at a fixed dosage of 5x109 CFU/day or placebo powder 
for five days per week for 10 months. The BB536 powder and placebo powder, which 
were imported from Morinaga Milk Industry Co., Ltd., Japan, have been manufactured 
under a HACCP certified manufacturing plant. The BB536 powder contains probiotic 
BB536 and dextrin as carrier while placebo contains 100% dextrin. Baseline 
questionnaires (Basic Lifestyle and Demographic Information Questionnaire) were 
distributed and collected before the intervention was started while monthly 
questionnaires (Health Condition Questionnaire) were distributed and collected every 
month. Fecal samples were collected at 0th, 5th and 10th month of the study for gut 
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microbiota profile and fecal immunoglobulin A (IgA) concentration analysis. Results 
showed no significant difference in diarrhea incidences and symptoms between the 
BB536 group and placebo group. Comparison of the symptoms of respiratory diseases 
indicated a significant reduction (P<0.05) in sore throat (P=0.018), but no significant 
reduction in fever (P=0.084), cough (P=0.087) and runny nose (P=0.087) in the BB536 
group compared with the placebo group at 95% confidence level. Fecal samples were 
analyzed by high-throughput sequencing amplicons derived from the V3-V4 region of 
the 16S rRNA gene. Comparison of relative abundance of species showed significant 
increment in the abundance of genera Bacteroides and Prevotella on BB536 intake 
which was postulated to regulate immune responses in the lung through short-chain 
fatty acids production.  Principal coordinate analysis showed significant clustering 
pattern of the gut microbiota at genus level in BB536 group where the microbiota 
clustered together while placebo group showed a more dispersed pattern, indicating a 
more similar microbiota composition within the treatment group. The concentrations 
of the fecal immunoglobulin A were not significantly different between placebo and 
BB536 groups. Both groups showed increment in IgA concentrations during wet 
season when infections were prone to occur. In conclusion, these results suggest that 
as well as changing the gut microbiota population, administration of BB536 may 
alleviate sore throat during respiratory infections but showed no significant reduction 
in other symptoms such as fever, cough and runny nose among young children in 
Malaysia. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Background 
 In the human body, abundant of microbial cells colonize on every surface, such 
as the skin, oral cavity, urogenital tract, gastrointestinal tract and respiratory tract 
(Gerritsen et al., 2011; Mikami et al., 2012; Picard et al., 2005; Putignani et al., 2014). 
Microbial colonization is much more preferred in gastrointestinal tract which harbours 
a huge and complex diversity of microorganisms including both pathogenic and 
beneficial bacteria as well as viruses (Glendinning and Free, 2014; Holzapfel, 2006; 
Sekirov et al., 2010). These diverse species of bacteria are pivotal in regulating the 
balance of the bacteria ecosystem in the gastrointestinal tract and maintain health of 
the human host (Schell et al., 2002). Imbalance of the intestinal microbiota 
composition could cause diarrhea and respiratory diseases, thus negatively influencing 
the host (Hawrelak and Myers, 2004).  
Acute diarrhea, gastroenteritis, inflammatory bowel disease (IBD), irritable 
bowel syndrome (Nicholson et al., 2012) and others are categorized as gastrointestinal 
diseases. Acute gastroenteritis is one of the major causes of morbidity among young 
children, resulting in significant health costs. Statistics showed that among infants and 
young children or preschool children, severe gastroenteritis is a worldwide concern, 
with two million hospitalizations of children under five years of age for diarrhea 
(Jungersen et al., 2014; Walker et al., 2012). In Malaysia, the reported cases of acute 
gastrointestinal diseases including acute diarrhea have been observed throughout the 
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year (Cheah et al., 2011; Hsu et al., 2005; Hung et al., 2006). Diarrhea is commonly 
defined as passage of three or more loose or watery stools in the last 24 hours (WHO, 
2013).  
Respiratory diseases, comprising of upper and lower respiratory tract 
infections, are the most common acute diseases among children. This had contributed 
to the major cause of the morbidity and mortality globally (Lehtoranta et al., 2014; 
Vouloumanou et al., 2009). The occurrence of respiratory tract infections is much 
dependent on the weather of the region (Rahman et al., 2014; Sam et al., 2010; 
Simonsen et al., 2011). For example, in Malaysia, most occurrences of respiratory tract 
infections among young children or preschool children peak in midyear which is 
during dry season (April to June) and during wet season in the year end (October to 
January) (Rahman et al., 2014; Sam et al., 2010). 
Probiotics are defined as “live microorganisms which when administered in 
adequate amounts confer a health benefit on the host” (FAO/WHO, 2006). Probiotic 
bacteria, which beneficially affect the host by improving the intestinal microbial 
balance, may affect the immune response, thus boosting the body system to combat 
against diseases (Hatakka et al., 2001).  
Several studies on probiotic prevention of acute diarrhea in daycare centres 
worldwide with the use of Bifidobacterium as probiotics (alone or in combination with 
Streptococcus thermophiles, Lactobacillus rhamnosus, Lactobacillus acidophilus), 
showed clear evidence of efficacy to reduce diarrhea-related symptoms and duration 
in a strain-dependent and dose-dependent manner (Allen et al., 2009; Guandalini, 2011; 
Kloster Smerud et al., 2008). 
Probiotics on the other hand have also gained increasing evidence as an 
effective prophylaxis in preventing respiratory tract infections by reducing the 
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incidence, duration, and/or severity of respiratory diseases, particularly upper 
respiratory tract infections (Gill et al., 2012; Lehtoranta et al., 2014). Among clinical 
trials conducted with Bifidobacteria strains, duration of respiratory infections and 
symptoms of respiratory infection such as fever, cough and rhinorrhea were 
significantly reduced, relative to placebo (Cazzola et al., 2010; Gerasimov et al., 2016; 
Hatakka et al., 2007; Leyer et al., 2009; Rerksuppaphol and Rerksuppaphol, 2012; 
Taipale et al., 2011; Taipale et al., 2016). 
Among all the previous studies done on probiotic effects on acute diarrhea and 
respiratory diseases, there are many different probiotic strains which showed their 
efficacy in reducing the occurrences and symptoms. Probiotic strain Bifidobacterium 
longum BB536 is recognised as one of the best-known probiotic strains in the world 
which is widely applied. It has been extensively studied in both clinical research and 
technical development for improving intestinal environment, prevention of diarrhea, 
alleviation of constipation as well as supporting immune system (Akatsu et al., 2013; 
Kondo et al., 2013; Namba et al., 2010; Yaeshima et al., 1997). However, to our 
knowledge, the efficacy of Bifidobacterium longum BB536 in respiratory and 
gastrointestinal diseases has not yet been clinically studied among children in Malaysia. 
Considering that past studies have reported positive outcomes of bifidobacteria in 
alleviating the symptoms of the diseases, we hypothesized that administration of 
Bifidobacterium longum BB536 could reduce the symptoms during the occurrence of 
acute diarrhea and respiratory diseases. As these infections are common and are major 
causes of children’s morbidity and mortality, in this project, we hope to resolve these 
global issues via bifido approach.  
More than 70% of all the microorganisms found in the human body can be 
found in the gastrointestinal tract (GIT). The composition of the gastrointestinal tract 
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microbiota varies between individuals (Claesson et al., 2012). Fecal microbiota 
profiles can be determined through pyrosequencing, to provide an insight into the 
association of the gastrointestinal microbiota with certain diseases and probiotic 
ingestion. Through the pyrosequencing, method of DNA sequencing, microbial 
diversity, mainly in the gastrointestinal tract and other different environments such as 
skin, vagina, nasopharynx and oropharynx can be better understood (Siqueira et al., 
2012).   Previous studies have indicated that probiotic administrations are able to 
modify the composition of the fecal microbiota (Kristensen et al., 2016). Hence, in 
this study, the putative changes of the fecal microbiota profile between probiotic group 
and placebo group will be further elucidated.  
Immunoglobulin (Ig) A concentration is affected by the presence of probiotics 
(Lopéz et al., 2011). It is responsible in protecting host against pathogens through 
immunomodulatory mechanism. It is also involved in regulating the balance of the 
intestinal microbiota by preventing the penetration of the enteric pathogens into the 
epithelial surface and clearing all the pathogens. IgA is the most abundant 
immunoglobulin class found in the body, primarily at the mucosal surfaces (Isolauri et 
al., 2001). It is mainly produced in the inductive sites known as Peyer’s patches (PPs) 
in the small intestines (Rios et al., 2015). The production of IgA is promoted by the 
presence of cytokine interleukin (IL) 17 which is activated by T-helper (Th) 17 (Blutt 
and Conner, 2013). Studies demonstrated that bifidobacteria enhanced the production 
of cytokines which promoted the secretion of IgA. Therefore, it was aimed to compare 
the difference of the IgA secretion between probiotic group and placebo group.  
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1.2 Aim and objectives of research 
  The aim of this study was to evaluate the effects of Bifidobacterium longum 
BB536 administered orally for a period of 10 months in reducing acute diarrhea and/or 
respiratory diseases among children in Malaysia. The specific objectives of this study 
were:  
1) To compare the severity of acute diarrhea between the subjects in 
Bifidobacterium longum BB536 group and placebo group for 10 months in 
terms of total days, total occurrences and number of symptoms occurred during 
the event of diarrhea.  
2) To compare the severity of upper respiratory diseases between the subjects in 
Bifidobacterium longum BB536 group and placebo group for 10 months in 
terms of total days, total occurrences as well as number and types of symptoms 
occurred during the event of respiratory diseases.   
3) To compare the changes of fecal microbiota profiles of the subjects in 
Bifidobacterium longum BB536 group and placebo group across 10 months. 
4) To compare Immunoglobulin (Ig) A concentration from fecal samples of the 
subjects in Bifidobacterium longum BB536 group and placebo group across 10 
months.  
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 Gastrointestinal microbiota  
Gastrointestinal tract of a human is densely populated with over 500-1000 
different species of bacteria, contributing to a total weight of several hundred grams 
(Gerritsen et al., 2011; Mikami et al., 2012; Makino et al., 2013; Picard et al., 2005; 
Sjogren et al., 2009). With its large surface area, equivalent to the size of a tennis court 
(200 m2), and richness in nutrients, human gastrointestinal tract contains over 70% of 
all the microorganisms in the human body (Holzapfel, 2006; Sekirov et al., 2010). 
Most of the bacteria present are obligate anaerobes and are found on epithelial surface, 
mucus layer in the intestine or intestinal lumen (Picard et al., 2005; Sekirov et al., 
2010). Four predominant bacterial phyla found in the human gastrointestinal tract are 
Firmicutes, Bacteroidetes, Proteobacteria, and Actinobacteria (Glendinning and Free, 
2014; Lee and O'Sullivan, 2010; Sartor and Mazmanlan, 2012).  
Homeostasis of the commensal microbiota in gastrointestinal ecosystem is 
pivotal in maintaining host’s health (Hawrelak and Myers, 2004; Miyazaki, 2015; 
Ohno, 2015). The gut microbiota are responsible for a multitude of important functions 
such as metabolizing exfoliated epithelial cells, complex carbohydrates to short chain 
fatty acids (SCFAs) (Rauch and Lynch, 2012; Sartor and Mazmanlan, 2012); 
production of essential vitamins (Glendinning and Free, 2014); drug metabolism and 
toxicity (Aw and Fukuda, 2015); fortification of intestinal epithelial barrier (Rauch 
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and Lynch, 2012); as well as modulation of immune responses in host (Hemarajata 
and Versalovic, 2013; Rauch and Lynch, 2012).  
Microbiota perturbation can lead to gastrointestinal disorders such as 
inflammatory bowel diseases (IBD), irritable bowel syndrome (Nicholson et al., 2012), 
diarrhea, constipation and necrotizing enterocolitis (NEC) (Hawrelak and Myers, 2004; 
Sartor and Mazmanlan, 2012; Schulz et al., 2014; Turroni et al., 2012); atopic diseases 
such as atopic dermatitis, allergic rhinitis, asthma and food allergy (Toh et al., 2012; 
Yesilova et al., 2012); and respiratory tract infections, namely URTIs and LRTIs 
(Vouloumanou et al., 2009).    
 
2.2 Emergence of probiotics  
Probiotics are defined as “live microorganisms which when administered in 
adequate amounts confer a health benefit on the host” (FAO/WHO, 2006). The word 
probiotic means “for life” which was derived from Greek “pro bios” (Soccol et al., 
2010). They were only known as beneficial bacteria at the beginning of the 20th century 
by a Russian Nobel Prize winner, Elie Metchnikoff who linked the health and 
longevity with the consumption of yogurt containing lactic-acid-producing bacteria 
(LAB) such as lactobacilli (Anukam and Reid, 2007; Gogineni et al., 2013; Rauch and 
Lynch, 2012; Soccol et al., 2010). Later in 1899, a French pediatrician, Henry Tissier, 
isolated Bifidobacteria from the fecal samples of breast-fed infants to treat diarrhea 
through their oral administration (Anukam and Reid, 2007; Gogineni et al., 2013; Lee 
and O'Sullivan, 2010; Soccol et al., 2010).  Since last century, bifidobacteria were 
highly recommended due to their potential health benefits (Lee and O'Sullivan, 2010).   
Progressing through the years, both community and health care providers are 
increasingly aware of the relation of nutrition, diet and health. Therefore, probiotics 
8 
 
have recently gained tremendous popularity and interest (Ringel et al., 2012). Statistics 
showed that the global market of the probiotics was worth $14.9 billion in 2007, nearly 
$16 billion in 2008, and $36.6 billion in 2015. The market value is expected to exceed 
$64 billion by 2023 (Dover, 2016). Probiotics are marketed for different applications, 
such as functional foods and beverage, dietary supplements in infant formula, food and 
nutritional supplements and also in animal feed (Soccol et al., 2010). Geographically, 
the global probiotic market is divided as the North America (United States), Europe 
(United Kingdom, France and Germany), Asia Pacific (China, Japan, India), Latin 
America (Brazil), Middle East and Africa. United Kingdom and Germany account for 
about 45% of the total probiotic market while Japan is the second largest market 
(BioMedTrends, 2017).  
 
2.3 Classification and beneficial effects of probiotics 
2.3.1 In-vitro studies  
To qualify as a probiotic, a viable bacterial strain must be safe for human use. 
Strains such as lactobacilli and bifidobacteria are commonly isolated from healthy 
human (Boyle et al., 2006; Isolauri et al., 2001; Kailasapathy and Chin, 2000; Soccol 
et al., 2010). The strain must be stable against bile, acid, enzyme and oxygen; able to 
adhere to intestinal mucosa; able to colonize in the human gastrointestinal tract; able 
to reduce pathogen adhesion to mucosal surfaces and able to produce antimicrobial 
substances (Boyle et al., 2006; FAO/WHO, 2002; Isolauri et al., 2001; Kailasapathy 
and Chin, 2000). In addition, the strain must be viable and metabolically active within 
gastrointestinal tract (Kailasapathy and Chin, 2000). General findings of the in-vitro 
studies of bifidobacteria are summarized in Table 2.1. 
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Table 2.1 Summary of the in-vitro studies involving bifidobacteria. 
Properties Findings 
Resistance to bile   B. longum, B. pseudocatenulatum and B. bifidum 
were able to grow in the presence of 2% of bovine 
bile (Delgado et al., 2008).  
 Bifidobacteria contain several genes and proteins, 
eg bile salt hydrolase and  bile efflux transporters 
which confer in bile resistance (Grimm et al., 2014) 
Resistance to acid  B. longum and B. pseudocatenulatum were still 
viable at low pH of 3.5 (Delgado et al., 2008) 
Adherence to intestinal 
mucosa 
 Strains of B. adolescentis, B. lactis, B. longum, B. 
bifidum, B. infantis and B. breve were reported to 
adhere to Caco-2, T84 and HT-29 cell lines in strain 
specific manner (Preising et al., 2010) 
Antimicrobial activity   Pathogenic C. difficile is a toxin-producing 
bacterium which normally causes diarrhea and 
colitis. In vitro analysis to test the ability of 
probiotic strains in inhibiting pathogen’s growth 
showed about 60.4% of C. difficile were killed after 
3 hours while 99.7% were killed after 24-hour 
incubation with B. breve and B. lactis (Lee et al., 
2013) 
Anti-inflammatory 
properties 
 Strains of bifidobacteria acted in a strain-dependent 
manner in inhibiting lipopolysaccharide-induced 
IL-8 secretion in both Caco-2 and T84 cell lines 
(Preising et al., 2010) 
IL: interleukin 
 
2.3.2 In-vivo studies and clinical trials 
Lactobacilli and bifidobacteria are common in exerting therapeutic and health 
benefits to the host by altering or modifying the host’s gastrointestinal microflora to 
restore microbial balance (Kailasapathy and Chin, 2000; Rauch and Lynch, 2012; 
Ritchie and Romanuk, 2012). They confer health benefits through enhancement of 
immune system, prevention of intestinal infections, alleviation of diarrhea, prevention 
of food allergy, anti-carcinogenic effect, prevention of upper gastrointestinal tract 
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diseases, improvement of lactose intolerance, prevention of hypercholesterolemia, 
prevention of osteoporosis and stabilization of the gastrointestinal mucosal barrier 
(Boyle et al., 2006; Hao et al., 2015; Kailasapathy and Chin, 2000; Rauch and Lynch, 
2012; Ringel et al., 2012; Soccol et al., 2010). A summary of the in-vivo findings is 
shown in Table 2.2. 
Probiotics have been widely studied in various clinical trials worldwide, 
applied in healthy or diseased conditions, involving subjects ranging from infants to 
the elderly. Clinical trials are referred to as research studies which are controlled 
scientifically with adherence to good clinical practices (GCP) for the evaluation of the 
safety and effectiveness of a therapeutic agent, involving human volunteers with their 
consent (Mahan, 2014; Thorat et al., 2010). Clinical trials can be conducted as 
randomized controlled trial or non-randomized controlled trial. Ideally, a clinical study 
should be randomized to ensure the allocation of subjects to the different treatment 
groups in a balanced manner to maximize the homogeneity between two groups 
(Meinert, 2012; Rohrig et al., 2009). Randomization can be stratified according to 
gender or age to produce a parallel ratio of subjects in both groups. A trial should also 
involve masking or blinding, either single-blind or double-blind. Single-blind is where 
only the subject enrolled is unaware which treatment is received while double-blind 
refers to both subject and investigator being unaware of which treatment is planned 
(Rohrig et al., 2009). Double-blind design is able to exclude possible factors such as 
sex, age or social differences, which will eventually affect the evaluation of the therapy 
and the measures of outcomes. A masked design of trial is more reliable than without 
blinding, therefore, ensure the quality of the study (Meinert, 2012). Besides, placebo-
controlled studies are also widely applied as well as in probiotic studies, where the 
group receiving desired probiotic strain is compared to the control group receiving 
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preparation containing no probiotic. This is widely applied to compare the 
effectiveness of the probiotic in alleviating or preventing certain medical conditions. 
 
Table 2.2 Summary of the in-vivo studies involving bifidobacteria. 
Properties Findings 
Resistance to bile   Resistance to bile is critical for the colonization of 
the GIT with microorganism for host health.  
 Recombinant strain of B. breve increased GIT 
persistence and protected the mice against infection 
of L. monocytogenes (Grimm et al., 2014) 
Adherence to intestinal 
mucosa 
 Bifidobacteria have been studied in healthy 
volunteers and patients at different dosage ranging 
from 106-1012 CFU/mL/day. Results showed that B. 
longum at dosage of 1011 CFU/mL/day for 40 days 
showed survival in the gut and lowered the 
population of pathogenic bacteria such as 
enterobacteriaceae and clostridia (Fujiwara et al., 
2001) 
 B. lactis strain BB12 at dosage of 106 CFU/mL/day 
showed prophylactic action against acute diarrhea in 
infants younger than 8 months (Chouragui et al., 
2004) 
Antimicrobial activity   Strains of bifidobacteria showed protective effects 
against infections caused by C. rodentium in mice 
model through the production of 
exopolysaccharides (EPS) and short chain fatty 
acids (SCFAs) (Grimm et al., 2014) 
Anti-inflammatory 
properties 
 B. bifidum reduced the inflammatory scores of 
trinitribenzene sulfonic acid (TNBS) colitis from 
4.7 to 3.2 (P=0.023) in murine model.  
 Appearance of the mice’s colon wall was normal 
and solid fecal was observed upon feeding with 
bifidobacteria  (Preising et al., 2010) 
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2.4 Bifidobacteria 
2.4.1 General features of bifidobacteria 
Bifidobacteria are known as one of the main potentially health-enhancing 
probiotic bacteria as they are natural predominant inhabitants in human gastrointestinal 
tract (Picard et al., 2005; Tan et al., 2015). Bifidobacteria show no health risk for they 
have a long history of consumption in the form of fermented milk (Picard et al., 2005). 
Bifidobacteria are generally characterized as high-G+C Gram-positive prokaryotes, 
non-spore-forming, non-motile, catalase-negative and obligate anaerobic bacteria (Lee 
and O'Sullivan, 2010; Martinez et al., 2013; Schell et al., 2002). They were described 
as pleomorphic rods with different shapes, including curved, short and bifurcated Y 
shapes (Martinez et al., 2013; Schell et al., 2002). They produce acetic and lactic acids 
through the bifid shunt pathway by metabolizing lactose, glucose, galactose and 
fructose (Lee and O'Sullivan, 2010; Wasilewska et al., 2003).  
Genus Bifidobacterium, belongs to the phylum Actinobacteria, which is one of 
the main phylum in the Bacteria domain (Lee and O'Sullivan, 2010). To-date, there 
are 32 species in the genus Bifidobacterium (Baffoni et al., 2013; Schell et al., 2002). 
They were isolated from different ecological niches, which are human gastrointestinal 
tract (GIT), oral cavity, food, animal gastrointestinal tract, insect intestine, and sewage 
(Bottacini et al., 2014; Ventura et al., 2012). Among these niches, human GIT contains 
the vast majority of bifidobacteria where they are naturally present as the dominant 
commensal colonic microbiota (Martinez et al., 2013; Picard et al., 2005; Schell et al., 
2002). In the human GIT, Bifidobacterium longum subsp. longum, B. longum subsp. 
infantis, B. pseudolongum, B. bifidum, B. animalis subsp. lactis, B. adolescentis, B. 
pseudocatenulatum, B. catenulatum, B. angulatum and B. breve are the most abundant 
bifidobacterial species (Grimm et al., 2014; Turroni et al., 2014; Ventura et al., 2012). 
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The population of bifidobacterial species and their compositions in humans vary across 
age. Martinez et al. (2013) and Grimm et al. (2014) reviewed that approximately 91% 
of the bifidobacteria were found in a newborn’s GIT while the composition was 
reduced to 3-7% in an adult’s GIT (Leke et al., 2007; Turroni et al., 2014). In addition, 
the composition of the bifidobacteria in infants is also different to than those in adults’ 
GIT, and the bifidobacteria are known as infant-specific and adult-specific 
bifidobacterial species. Infant-specific bifidobacterial species are B. breve, B. bifidum, 
and B. longum subsp. infantis while adult-specific bifidobacterial species are   B. 
adolescentis, B. catenulatum/pseudocatenulatum, and B. longum subsp. longum 
species (Ventura et al., 2012).  
 
2.4.2 Health benefits  
Bifidobacteria colonization of the gastrointestinal tract during infancy is 
critical as it was reviewed that insufficient colonization resulted in abuse of antibiotics, 
causing inflammation, autoimmune and atopic diseases (Dong et al., 2010; Gueimonde 
et al., 2007; Gill et al., 2012). Establishment of bifidobacteria is also vital in 
modulation of immune system and anti-inflammatory role on the mucosal surface 
(Mikami et al., 2009). Also, studies showed that bifidobacteria are able to break down 
indigestible polysaccharides into readily absorbed short chain fatty acids (SCFAs), 
leading to an increase of bifidobacterial populations in the gastrointestinal tract, as 
well as promoting enrichment of the other beneficial bacteria in the lower 
gastrointestinal tract where they can utilize the SCFAs (Fushinobu, 2010; Kitaoka, 
2012; Lee and O'Sullivan, 2010; Pokusaeva et al., 2011). The high number of 
bifidobacteria in infants as compared to that in adults may correlate with the low levels 
of putrefactive products such as ammonia, indole, p-cresol and phenol (Lee and 
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O'Sullivan, 2010). This suggests that supplementation of bifidobacteria can restore the 
homeostasis of intestinal microflora.  
Members of the genus bifidobacterium have been extensively studied for their 
health benefits on the host. Bifidobacteria have been reported in reducing or treating 
numerous diseases such as acute diarrhea, necrotizing entercolitis, constipation, atopic 
diseases and respiratory tract infections as well as preventing infections through 
competitive exclusion ( Lau et al., 2015; O'Callaghan and van Sinderen, 2016). Several 
studies, including human studies have been carried out to understand the possible 
mechanisms of the bifidobacteria in reducing or treating the diseases (Table 2.3). 
 
2.4.3 Bifidobacterium longum BB536 
 Bifidobacterium longum BB536 is one of the best-known probiotic strains in 
the world. It was originally isolated from a healthy infant back in 1969 in Japan. It has 
been widely applied in milk, yogurt, infant formula the dairy industry, and as health 
supplements, which are commercially available in more than 30 countries, including 
Malaysia and Japan. B. longum BB536 is manufactured by Morinaga Milk Industry 
Co., Ltd., Japan.  
B. longum BB536 has been extensively studied in both clinical research and 
technical development with more than 100 scientific publications. Based on in-vitro, 
in-vivo and clinical studies, BB536’s long consumption history of more than 30 years, 
supports the safety and health benefits of the strain. These include improving intestinal 
environment, prevention of diarrhea, alleviation of constipation as well as supporting 
immune system (Akatsu et al., 2013; Kondo et al., 2013; Namba et al., 2010; 
Yaeshima et al., 1997).  
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Table 2.3 Health benefits of bifidobacteria in different diseases 
No. Diseases/Conditions Possible mechanisms of bifidobacteria Outcomes from clinical studies 
1. Acute diarrhea  Modulation of the host immune system 
 Restoration of the composition of GIT 
microbiota 
 Production of bacteriocins and SCFAs to alter 
pH of GIT 
 Inhibit colonization of enteropathogens 
 Reduced in mean duration of diarrhea 
 Lower concentrations of fecal rotavirus and E. coli in rotavirus diarrhea 
 Downregulation of pro-inflammatory cytokine such as TNF-α 
 Upregulation of anti-inflammatory cytokines such as IL-10 and IFN-γ 
(Allen et al., 2009; Shu et al., 2001; Salari et al., 2012) 
2. Necrotizing 
enterocolitis (NEC) 
 Improve development of cellular junctional 
proteins in the intestinal epithelium  
 Promote production of IgA  
 Enhance production of anti-inflammatory 
cytokines 
 Incidence of NEC was reduced from 57% to 17%  
 Suppressed TLR4-triggered inflammatory responses  
(Khailova et al., 2009) 
3. Constipation   Promote reduction in pH through production 
of SCFAs and prevents colonization with 
pathogenic bacteria 
 Stimulation of water and electrolyte secretion 
 Decrease colonic transit time 
 Increased defecation frequency  and mean stool consistency score 
 Decreased pain during defecation, episodes of fecal incontinence and 
abdominal pain 
(Tabbers et al., 2011) 
4. Atopic disease  Modulation of immune responses  
 Activation of dendritic cells and skewing of T-
helper (Th1/Th2) 
 Upregulation on anti-inflammatory cytokines 
such as interferon (IFN)-γ 
 Reduced allergic symptoms  
 Decreased the atopic dermatitis scores (SCORAD) from 16 to 0 after 2 
months of intervention 
(Michail, 2009; Taniuchi et al., 2005; Xiao et al., 2006; Yesilova et al., 
2012) 
5. Respiratory tract 
infections  
 Increasing immune cell activity 
 Increasing local and systemic antibody 
production 
 Inducing phenotypic changes in dendritic cells 
 Sig. reduction in the incidence and duration of fever, coughing and 
rhinorrhea 
 Lower no. of subjects experienced episodes of respiratory infections 
compared to control group. 
 Fewer episodes of fever 
(Taipale et al., 2011; Weizman et al., 2005) 
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2.5 Respiratory diseases  
Acute respiratory infections (ARI) and chronic respiratory infections are the 
common examples of respiratory diseases. They represent one of the major health 
issues among children. Statistically, acute respiratory infections are responsible for 
pediatric morbidity and mortality among children under five years old (Araujo et al., 
2015; Madhi and Klugman, 2006; Simoes et al., 2006; Wang et al., 2016). It is 
estimated that 1.9 million to 2.2 million of children died of acute respiratory infection 
worldwide annually (Madhi and Klugman, 2006). Acute respiratory infections also 
accounted for approximately 60% of all pediatric illnesses, 22-26.7% of all 
hospitalizations and 33.5-59% of all general practitioner consultations (Gerasimov et 
al., 2016; Simoes et al., 2006; Tregoning and Schwarze, 2010). Economically, acute 
respiratory infections have resulted in significant impact on the health care 
infrastructure among countries (Gerasimov et al., 2016; Tregoning and Schwarze, 
2010; Wang et al., 2016). As the acute respiratory infections among children are still 
a great global challenge for public health, effective treatments and prophylaxes for the 
acute respiratory infections are of utmost importance.   
Acute respiratory infections can be classified as upper respiratory tract 
infections (URTI) and lower respiratory tract infections (LRTI). The URTI is referred 
to the infection that occurs in the airways from the nostrils to the vocal cords in the 
larynx. This includes conditions such as common cold, otitis media, pharyngitis, 
laryngitis and sinusitis. URTIs are known as the most common infectious diseases 
(Simoes et al., 2006). The LRTI refers to the infection occurring in the airways from 
the trachea and the bronchi to the bronchioles and the alveoli, for example bronchitis 
and pneumonia (Araujo et al., 2015; Simoes et al., 2006; Tregoning and Schwarze, 
2010; Thompson et al., 2013; Wang et al., 2016). Such acute respiratory infections are 
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mostly caused by rhinoviruses (RSVs), parainfluenza and influenza viruses, human 
metapneumovirus, and adenoviruses (Simoes et al., 2006). Common symptoms found 
in acute respiratory infections are fever, runny nose, nasal congestion, sore throat, 
cough, sneezing, increased mucus production or wheezing (Agustina et al., 2012; 
Cazzola et al., 2010; Eccles, 2007; Gerasimov et al., 2016; Kumpu et al., 2012; 
Rerksuppaphol and Rerksuppaphol, 2012; Thompson et al., 2013; Wang et al., 2016). 
However, symptoms developed in LRTI are generally more severe than that in URTI. 
These include severe cough, breathlessness, respiratory distress or reduced breath 
sounds due to trapping of air and peripheral hyperinflation of the lung. Therefore, 
LRTI might be a great threat to the children and hospitalization is usually required 
(Tregoning and Schwarze, 2010; Wang et al., 2016).  
In Malaysia, it was reviewed (Sam et al., 2010) that the occurrence of acute 
respiratory infections is seasonal, where the occurrences peak in midyear (during the 
month of May) and year end (months of November and December). The dry season 
reported during midyear while wet season at year end in Malaysia potentially resulted 
in the occurrence of ARIs (Rahman et al., 2014; Saat et al., 2010; Sam, 2015). During 
the dry season, the number of particulates such as smoke, dust, pollen, soot and liquid 
droplets suspended in the air increased. In industrialized area, haze or air pollution as 
a result from deforestation and land-clearing also increased the number of particle 
pollutions in the air. The particle pollutions may trigger the inflammation process in 
the respiratory tract and promote the access of pathogenic microorganisms into the 
airways and develop inflammation (Rosa et al., 2008; Tekverk et al., 2015). On the 
other hand, elevated humidity due to excess rainfall encouraged the development of 
fungi and certain viruses with seasonal behaviour, resulting in conditions such as 
cough, allergy and respiratory tract infections among children (Rosa et al., 2008). 
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2.5.1 Effects of probiotics on respiratory diseases: in-vivo evidences 
To-date, there are accumulating evidences through clinical trials showing that 
probiotics exhibit positive effects in the alleviation of acute respiratory infections in 
both children and adults (Araujo et al., 2015; Cazzola et al., 2010; Gerasimov et al., 
2016; Rerksuppaphol and Rerksuppaphol, 2012; Taipale et al., 2016). Children who 
attend day care centres or preschools are especially exposed to higher risk of acquiring 
acute respiratory infections. This is due to their close physical contact among children 
that favours the transmission of infectious diseases. In a clinical study done in Finland 
of children receiving either probiotic L. rhamnosus GG in milk, the days of day care 
absenteeism due to illness was significantly lesser when compared with control group. 
In addition, children in the L. rhamnosus GG group had fewer respiratory tract 
infections with complications (otitis media, sinusitis, bronchitis and pneumonia) and 
less prescribed antibiotic treatments (Lehtoranta, 2012). Lactobacillus group showed 
significantly longer duration without respiratory symptoms as compared to the control 
group (Hatakka et al., 2001). Another study done in Croatia where children attending 
day care were randomly allocated to either receiving L. rhamnosus GG in milk or 
placebo for three months, the children in L. rhamnosus GG group were observed to 
have significantly reduced risk of upper respiratory tract infection that lasted more than 
three days (Hojsak et al., 2010). The effects of a probiotic mixture on alleviation of 
respiratory illnesses were also investigated by Hatakka and his colleagues (2007) in 
Finland among the otitis-prone children from 10 months to six years of age. This 
placebo-controlled study involved 24 weeks of intervention with capsule containing 
mixture of Lactobacillus rhamnosus GG, L. rhamnosus LC705, Bifidobacterium  
breve 99 and Propionibacterium freudenreichii JS showed reduction in the occurrence 
of recurrent respiratory illness. When the effects of probiotics were studied on the 
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respiratory pathogens in the nasopharyngeal airway, the number of human bocavirus 
was reduced significantly in the nasopharynx of these children, indicating that 
probiotics may be more effective against respiratory tract infections of viral origin 
(Lehtoranta, 2012). Also, administration of Bifidobacterium longum BB536 was 
shown to alleviate symptoms of the respiratory infections (Xiao et al., 2006; Xiao et 
al., 2007). Namba et al. (2010) also reported that the incidence and occurrence of 
influenza were significantly lower in Bifidobacterium longum BB536 group, relative 
to the placebo group.  
 
2.5.2 Clinical studies on the effects of bifidobacteria on respiratory diseases 
Bifidobacteria had been extensively evaluated for their efficacies in preventing 
or reducing incidences of respiratory diseases, particularly in upper respiratory tract 
infections (URTI) (Gill et al., 2012; Lehtoranta et al., 2014). Collectively, a number 
of randomized controlled trials showed positive outcomes of the administration of 
bifidobacteria in reducing the incidences as well as symptoms of respiratory diseases 
among subjects aged from one month up to 12 years old (Cazzola et al., 2010; 
Gerasimov et al., 2016; Hatakka et al., 2007; Leyer et al., 2009; Rerksuppaphol and 
Rerksuppaphol, 2012; Taipale et al., 2011) but a few showed no effect on the 
incidences (Hojsak et al., 2015; Hojsak et al., 2016; Kloster Smerud et al., 2008) 
(Table 2.4). 
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Table 2.4 Randomized, placebo-controlled trials involving bifidobacteria strains in respiratory diseases.  
i) Trials with positive outcomes 
Treatment Probiotic strains Dosage 
(Duration of 
study) 
Age range Subjects 
(Randomized); 
(included in the 
analysis) 
Outcomes Country Reference 
Common 
winter 
diseases 
L. helveticus R0052,  
B. infantis R0033, 
B. bifidum R0071 
3 x 109 CFU/day  
(3 months) 
3 – 7 years 
old 
135  
(62T/73P); 
(62T/73P)  
 No. of children suffered at least 
one ENT  and respiratory tract 
disorder symptoms reduced 
France Cazzola et al., 
2010 
Acute 
respiratory 
infections 
(ARI) 
L. acidophilus DDS-1 
(NCIMB 30333), 
B. lactis UABLA-12 
(NCIMB 30334) 
5 x 1010 CFU/day 
(14 days or till 
resolution of 
secondary ARI) 
3 – 12 years 
old 
210  
(113T/112P); 
(113T/112P) 
 Time to resolution of the 
secondary ARI was shorter 
 Median severity of ARI was lower 
Ukraine Gerasimov et al., 
2016 
Acute  
otitis media 
L. rhamnosus GG 
(ATCC53103), 
L. rhamnosus LC705,  
B. breve 99, 
P. freudenreichii spp. 
shermanii JS 
8-9 x 109 
CFU/capsule of 
each strain, 1 
capsule/day  
(6 months) 
10 months – 
6 years old 
309 
(155T/154P); 
(135T/134P) 
 Tendency in reducing recurrent of 
respiratory infections 
Finland Hatakka et al., 
2007 
Common cold L. acidophilus, 
B. bifidum  
109 bacteria 
each/capsule; 2 
capsules/day 
(3 months) 
8 – 13 years 
old 
80  
(40T/40P); 
(40T/40P) 
 Symptoms of common cold (fever, 
cough, rhinorrhea) reduced 
Thailand Rerksuppaphol 
and 
Rerksuppaphol, 
2012 
*Intervention 1: 110/110; Intervention 2: 112/112 
AOM= Acute otitis media; ENT=ear, nose and throat; P=placebo; T=intervention; CFU=colony forming unit
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 Continued Table 2.4 
ii) Trials with insignificant outcomes 
Treatment Probiotic strains Dosage 
(Duration of 
study) 
Age range Subjects 
(Randomized); 
(included in the 
analysis) 
Outcomes Country Reference 
Respiratory 
tract 
infections 
B. animalis subsp. 
lactis  
109 CFU/day 
(entire duration 
of 
hospitalization) 
1 – 18 
years old 
727  
(362T/365P); 
(362T/365P) 
 No significant in incidence, 
duration and severity of 
respiratory tract infections 
 No significant in duration of 
hospitalization 
 No significant in antibiotic use  
Croatia Hojsak et 
al., 2015 
Respiratory 
tract 
infections 
L. rhamnosus GG and 
L. acidophilus LA-5,  
B. lactis BB-12 
109 CFU/day of 
Lactobacillus 
107 CFU/day of 
BB-12 
(7 months) 
12 – 36 
months 
240  
(117T/123P); 
(97T/102P) 
 No significant in days of 
respiratory symptoms 
Norway Kloster 
Smerud et 
al., 2008 
Common  
infections 
B. animalis subsp. 
lactis 
109 CFU/day 
(3 months) 
1 – 8 years 
old 
210  
(104T/106P); 
(104T/106P) 
 No significant in number of 
children with infections 
 No significant in the duration of 
respiratory infections 
Croatia Hojsak et 
al., 2016 
Infectious 
diseases 
B. animalis subsp. 
lactis BB-12 
(DSM15954) 
1 x 1011 
CFU/day 
(7 months) 
1 – 2 
months 
109 
(55T/54P); 
(34T/35P) 
 Reduced incidence of 
respiratory infection   
 No significant on fever 
episodes, antibiotic treatments, 
AOM 
Finland Taipale et 
al., 2011 
*Intervention 1: 110/110; Intervention 2: 112/112 
AOM= Acute otitis media; ENT=ear, nose and throat; P=placebo; T=intervention; CFU=colony forming unit
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2.6 Gastrointestinal diseases 
Gastrointestinal diseases include irritable bowel syndrome (Nicholson et al., 
2012), inflammatory bowel diseases (IBD), Helicobacter pylori infection, necrotizing 
enterocolitis (NEC), pouchitis, antibiotic associated diarrhea (AAD), Clostridium 
difficile-associated diarrhea (CDD), traveler’s diarrhea, infectious diarrhea and acute 
diarrhea (Ringel et al., 2012; Ritchie and Romanuk, 2012). Among these 
gastrointestinal diseases, acute diarrhea is the second leading cause of morbidity and 
mortality among children under five years of age globally, such that nearly 1.7 billion 
cases of diarrhea and 760 thousand cases of diarrhea-related death are reported every 
year (Ahmadi et al., 2015; Kolader et al., 2013; WHO, 2013). While in the year 2015, 
WHO claimed that as many as 5.9 million children under five years of age died due to 
preventable diseases including diarrhea (WHO, 2016). Among the children in this age 
group, those attending day care centres or preschool are 2-3 times higher risk in 
acquiring acute gastrointestinal infections like diarrhea (Hatakka et al., 2001; Hojsak 
et al., 2016; Kloster Smerud et al., 2008). Diarrhea is commonly defined as three or 
more loose or watery stools in the last 24 hours (WHO, 2013). 
In Malaysia, reported cases of acute diarrhea and gastroenteritis have been 
observed throughout the year, with rotavirus-associated diarrhea being the most 
identified gastrointestinal disorder (Cheah et al., 2011; Hsu et al., 2005; Hung et al., 
2006). Although data on the occurrence of gastrointestinal diseases, specifically for 
children are rare, general data from the Malaysian population revealed that acute 
diarrhea occurrence happened throughout the year with several peaks in the early of 
the year (month of January), midyear (month of May till July) and year end (months 
of November and December) (Cheah et al., 2011; Hsu et al., 2005).  
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Evidences suggested that gastrointestinal diseases have been linked to 
dysbiosis or imbalance of the gastrointestinal microbial community (Lau et al., 2015; 
Rauch and Lynch, 2012; Ringel et al., 2012; Ritchie and Romanuk, 2012). Dysbiosis 
is referred to as “qualitative and quantitative changes in the intestinal flora, their 
metabolic activity and their local distribution” (Hawrelak and Myers, 2004). 
Perturbations in the microbial communities may contribute to disease susceptibility 
(Hemarajata and Versalovic, 2013).  
 
2.6.1 Effects of probiotics on gastrointestinal diseases: in-vivo evidences 
Emerging evidences showed that probiotic supplementation is able to 
ameliorate diseases by restructuring the microbiota community (Forbes et al., 2016; 
Hemarajata and Versalovic, 2013; Hojsak et al., 2016; Kloster Smerud et al., 2008; 
Rauch and Lynch, 2012; Ringel et al., 2012). In several randomized, double-blind and 
placebo-controlled studies on probiotic prevention of acute diarrhea in daycare centres 
worldwide, probiotics tested such as Lactobacillus GG, Bifidobacterium lactis (alone 
or in combination with Streptococcus thermophiles), L. reuteri, L. casei and L. 
acidophilus showed a clear evidence of  efficacy to reduce diarrhea-related symptoms 
in a strain-dependent and dose-dependent manner (Guandalini, 2011; Kloster Smerud 
et al., 2008). Out of the 15 clinical studies reviewed, participants who were 
administered probiotics were less likely to have diarrhea lasting more than three days, 
indicating the efficacy of probiotics not only in preventing occurrence of diarrhea, but 
also in treating episodes of diarrhea. Additionally, it was found that probiotics intake, 
as was reported in 12 studies performed on infants and children, reduced the mean 
duration of diarrhea by 29.20 hours (Allen et al., 2009). In the study by Grandy et al. 
(2010), the effect of probiotics Lactobacillus acidophilus, L. rhamnosus, B. longum 
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and Saccharomyces boulardii also showed that intervention groups had a shorter time 
of vomiting periods as compared with controls, during the probiotics treatment of acute 
rotavirus diarrhea. Also, a clinical study carried out by Colombel et al. (1987) showed 
that with the administration of yogurt containing B. longum BB536, there was no 
diarrhea case reported among 10 adult volunteers. They also found a great decrease in 
the numbers of fecal Clostridium in the B. longum BB536 administered group 
compared to that of the placebo group.  
 
2.6.2 Clinical studies on the effects of bifidobacteria on gastrointestinal diseases 
There are increasing evidence reported that bifidobacteria demonstrated 
positive effects on various gastrointestinal diseases. However, the evidences are still 
limited (Table 2.5).  In a study done by Weizman and colleagues (2005), two 
interventions using two probiotics strains: Bifidobacterium lactis (BB-12) and 
Lactobacillus reuteri (55730) which were supplemented in cow’s milk formula 
showed significant reduction in days with diarrhea and episodes of diarrhea in both 
probiotics groups. Besides, another study which involved children attending day-care 
exhibited a significant (P=0.020) reduction in the treatment group receiving probiotic 
milk drink containing a combination of three lactic acid bacteria: LGG, L. acidophilus 
LA-5 and Bifidobacteria Bb-12 (Kloster Smerud et al., 2008).  
 Bifidobacteria are also effective in ameliorating antibiotic-associated diarrhea 
(Picard et al., 2005). A study done by Corrêa et al. (2005) which involved the 
administration of commercial probiotic formula containing Bifidobacterium lactis and 
Streptococcus thermophiles, showed a significant lower in the number of antibiotic-
associated diarrhea (AAD), 16.3% in treatment group as compared to 31.2% in placebo 
group.  
